resveratrol has been researched along with rasagiline in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Duarte, P; Estrada-Valencia, M; Fernández-Mendívil, C; Herrera-Arozamena, C; León, R; Lombardía, J; López, MG; López-Caballero, P; Michalska, P; Morales-García, JA; Pérez, C; Pérez-Castillo, A; Rodríguez-Franco, MI; Sastre, ED; Senar, S | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Ding, Y; Hou, JW; Lan, JS; Liu, Y; Xie, SS; Yang, J; Zhang, T; Zhang, XY; Zhao, Y | 1 |
1 review(s) available for resveratrol and rasagiline
| Article | Year |
|---|---|
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
3 other study(ies) available for resveratrol and rasagiline
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
Topics: Antioxidants; Ligands; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Resveratrol | 2022 |
Design, synthesis and evaluation of resveratrol-indazole hybrids as novel monoamine oxidases inhibitors with amyloid-β aggregation inhibition.
Topics: Amyloid beta-Peptides; Animals; Catalytic Domain; Cell Survival; Curcumin; Drug Design; Humans; Indans; Indazoles; Iproniazid; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Multimerization; Rats; Resveratrol | 2018 |